FDA Brief

Warning letters Drugs

FDA warning letter to

Cosmobeauti Laboratories & Manufacturing Inc.

High riskIssued Aug 11, 2023Posted Aug 29, 2023Center for Drug Evaluation and Research | CDER

FDA warns Cosmobeauti Laboratories over manufacturing rule violations for OTC sunscreen drugs, including backdated batch records and missing microbial testing.

What happened

FDA inspected the drug manufacturing facility from March 6 to March 15, 2023. The agency found that the quality unit failed to oversee OTC SPF sunscreen drug production, and a consultant told investigators that review steps on batch production records were backdated. FDA also cited missing microbiological testing for each batch, insufficient shelf-life stability data, incomplete batch records, and inadequate water system and cleaning validation.

What FDA found

  1. The quality unit failed to ensure that OTC sunscreen drug products were made in compliance with manufacturing rules and met specifications.

    21 CFR 211.22
  2. Review steps on batch production records were backdated instead of recorded when performed.

    21 CFR 211.22
  3. The firm did not perform microbiological testing on each finished drug batch.

    21 CFR 211.165(b)
  4. The firm lacked sufficient stability data to support the assigned shelf-life of its OTC drug products.

    21 CFR 211.166(b)
  5. Batch production records lacked major equipment, critical steps and parameters, and numerous steps were not recorded.

    21 CFR 211.100(a) and 21 CFR 211.188
  6. The firm lacked adequate validation of the water system used to rinse non-dedicated equipment and lacked cleaning validation for that equipment.

    21 CFR 211.100(a)

What FDA wants

FDA asks Cosmobeauti to correct the violations and respond in writing within 15 working days with corrective actions and evidence. FDA also recommends a qualified CGMP consultant to audit operations and evaluate corrective actions.

Who should pay attention

  • brands that contract with Cosmobeauti to make OTC sunscreen drugs
  • distributors and retailers selling its OTC sunscreen products
  • contract manufacturers and quality teams handling similar documentation and cleaning validation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk